Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer

Chinese Medical Journal

Volumn 124, Issue 2, 2011, Pages 199-204

  Zhang, Bai Lin ^a   Sun, Tong ^a   Zhang, Bao Ning ^a   Zheng, Shan ^a   Lü, Ning ^a   Xu, Bing He ^a   Wang, Xiang ^a   Chen, Guo Ji ^a   Yu, Dian Ke ^a   Lin, Dong Xin ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Breast neoplasms; Drug therapy; Glutathione S transferase polymorphisms

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; ISOLEUCINE; PROGESTERONE RECEPTOR; VALINE;

ADJUVANT THERAPY; ADULT; ADVERSE DRUG REACTION; AGE; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; CYP3A GENE; DNA POLYMORPHISM; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; GSTP1 GENE; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MDR1 GENE; MENOPAUSE; MULTIPLE CYCLE TREATMENT; PHARMACOGENETICS; PRIMARY TUMOR; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79551704599     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.02.008     Document Type: Article

References (24)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.CA Cancer J Clin 2005; 55: 74-108.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
3. Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005; 330: 217.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
5. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-491.
6. Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549.
7. Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 2005; 6: 780-789.
8. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
9. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th ed. New York: Springer. 2002.
10. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS 2003. http://ctep.cancer.gov.
11. Levine MN, Whelan T. Adjuvant chemotherapy for breast cancer--30 years later. N Engl J Med 2006; 355: 1920-1902.
12. Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005; 97: 116-126.
13. Chia S, Swain SM, Byrd DR, Mankoff DA. Locally advanced and inflammatory breast cancer. J Clin Oncol 2008; 26: 786-790.
14. Sims AH, Howell A, Howell SJ, Clarke RB. Origins of breast cancer subtypes and therapeutic implications. Nat Clin Pract Oncol 2007; 4: 516-525.
15. Kapp AV, Jeffrey SS, Langerød A, Børresen-Dale AL, Han W, Noh DY, et al. Discovery and validation of breast cancer subtypes. BMC Genomics 2006; 7: 231.
16. Roy P, Yu LJ, Crespi CL, Waxman DJ. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 1999; 27: 655-666.
17. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003; 22: 7369-7375.
18. Johansson AS, Stenberg G, Widersten M, Mannervik B. Structure-activity relationships and thermal stability of human glutathione transferase P1-1 governed by the H-site residue 105. J Mol Biol 1998; 278: 687-698.
19. Yang G, Shu XO, Ruan ZX, Cai QY, Jin F, Gao YT, et al. Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer 2005; 103: 52-58.
20. Dasgupta RK, Adamson PJ, Davies FE, Rollinson S, Roddam PL, Ashcroft AJ, et al. Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood 2003; 102: 2345-2350.
21. Synold TW, Newman EM, Carroll M, Muggia FM, Groshen S, Johnson K, et al. Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity. Clin Cancer Res 1998; 4: 2349-2355.
22. de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 2005; 44: 1135-1164.
23. Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A, Wheeler C, et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992; 10: 995-1000.
24. Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics 2008; 18: 515-523.